Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate the clinical course of HBV infection and IBD and to analyze liver dysfunction risks in patients undergoing anti-TNF-α therapy. Methods: This retrospective multinational study involved multiple centers in Korea, China, Taiwan, and Japan. We enrolled IBD patients with chronic or resolved HBV infection, who received anti-TNF-α therapy. The patients’ medical records were reviewed, and data were collected using a web-based case report form. Results: Overall, 191 patients (77 ulcerative colitis and 114 Crohn’s disease) were included, 28.3% of whom received prophylactic antivirals. During a median follow-up duration of 32.4 months, 7.3% of patients experienced liver dysfunction due to HBV reactivation. Among patients with chronic HBV infection, the proportion experiencing liver dysfunction was significantly higher in the non-prophylaxis group (26% vs 8%, p=0.02). Liver dysfunction occurred in one patient with resolved HBV infection. Antiviral prophylaxis was independently associated with an 84% reduction in liver dysfunction risk in patients with chronic HBV infection (odds ratio, 0.16; 95% confidence interval, 0.04 to 0.66; p=0.01). The clinical course of IBD was not associated with liver dysfunction or the administration of antiviral prophylaxis. Conclusions: Liver dysfunction due to HBV reactivation can occur in HBV-infected IBD patients treated with anti-TNF-α agents. Careful monitoring is needed in these patients, and antivirals should be administered, especially to those with chronic HBV infection.
Abstract
Background/Aims: Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate the clinical course of HBV infection and IBD and to analyze liver dysfunction risks in patients undergoing anti-TNF-α therapy. Methods: This retrospective multinational study involved multiple centers in Korea, China, Taiwan, and Japan. We enrolled IBD patients with chronic or resolved HBV infection, who received anti-TNF-α therapy. The patients’ medical records were reviewed, and data were collected using a web-based case report form. Results: Overall, 191 patients (77 ulcerative colitis and 114 Crohn’s disease) were included, 28.3% of whom received prophylactic antivirals. During a median follow-up duration of 32.4 months, 7.3% of patients experienced liver dysfunction due to HBV reactivation. Among patients with chronic HBV infection, the proportion experiencing liver dysfunction was significantly higher in the non-prophylaxis group (26% vs 8%, p=0.02). Liver dysfunction occurred in one patient with resolved HBV infection. Antiviral prophylaxis was independently associated with an 84% reduction in liver dysfunction risk in patients with chronic HBV infection (odds ratio, 0.16; 95% confidence interval, 0.04 to 0.66; p=0.01). The clinical course of IBD was not associated with liver dysfunction or the administration of antiviral prophylaxis. Conclusions: Liver dysfunction due to HBV reactivation can occur in HBV-infected IBD patients treated with anti-TNF-α agents. Careful monitoring is needed in these patients, and antivirals should be administered, especially to those with chronic HBV infection.
참고문헌 (33)
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
- Jamilya Kaibullayeva, "Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study", Intestinal research, 18(4), pp.430~437 (2020), 대한장연구학회[DOI]
- Lee KM, "Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis : a Korean multicenter retrospective study", J Gastroenterol Hepatol, 28, pp.1829~1833 (2013)
- 최창환, "궤양성 대장염 치료 가이드라인", 대한소화기학회지, 59(2), pp.118~140 (2012), 대한소화기학회
- 예병덕, "크론병 치료 가이드라인", 대한소화기학회지, 59(2), pp.141~179 (2012), 대한소화기학회
- Merican I, "Chronic hepatitis B virus infection in Asian countries", J Gastroenterol Hepatol, 15, pp.1356~1361 (2000)
- Chan HC, "Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region", BMC Gastroenterol, 16, pp.100~ (2016)
- Loras C, "Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies : multicenter prospective observational study(REPENTINA 3)", J Crohns Colitis, 8, pp.1529~1538 (2014)
- Kim ES, "Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area : inadequate protective antibody levels in young patients", J Clin Gastroenterol, 48, pp.553~558 (2014)
- Ganem D, "Hepatitis B virus infection : natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
- Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
- Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)
- Ryu HH, "Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents : a retrospective analysis of 49cases", Clin Rheumatol, 31, pp.931~936 (2012)
- Tamori A, "Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy : evaluation of both HBsAg-positive and HBsAg-negative cohorts", J Gastroenterol, 46, pp.556~564 (2011)
- Rahier JF, "Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease", J Crohns Colitis, 8, pp.443~468 (2014)
- Reddy KR, "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.215~219 (2015)
- Farraye FA, "ACG clinical guideline : preventive care in inflammatory bowel disease", Am J Gastroenterol, 112, pp.241~258 (2017)
- 예병덕, "크론병 진단 가이드라인", 대한소화기학회지, 53(3), pp.161~176 (2009), 대한소화기학회
- 최창환, "궤양성 대장염 진단 가이드라인", 대한소화기학회지, 53(3), pp.145~160 (2009), 대한소화기학회
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Park SH, "Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases", Inflamm Bowel Dis, 18, pp.2004~2010 (2012)
- Papatheodoridis GV, "Therapeutic strategies in the management of patients with chronic hepatitis B virus infection", Lancet Infect Dis, 8, pp.167~178 (2008)
- Esteve M, "Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients : need for primary prophylaxis", Gut, 53, pp.1363~1365 (2004)
- Lan JL, "Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy", Ann Rheum Dis, 70, pp.1719~1725 (2011)
- Lee YH, "Hepatitis B virus(HBV)reactivation in rheumatic patients with hepatitis core antigen(HBV occult carriers)undergoing anti-tumor necrosis factor therapy", Clin Exp Rheumatol, 31, pp.118~121 (2013)
- Soo-Kyung Park, "Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases", Intestinal research, 18(1), pp.18~33 (2020), 대한장연구학회
- Hsu C, "A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma : a randomized trial", Hepatology, 47, pp.844~853 (2008)
- Michel M, "Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease", J Rheumatol, 30, pp.1624~1625 (2003)
- Vaughn BP, "Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy", Inflamm Bowel Dis, 18, pp.1057~1063 (2012)
- Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
- Zhang MY, "Systematic review with network meta-analysis : comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation", Oncotarget, 7, pp.30642~30658 (2016)